Abstract: An electric pulse decomposition method for separating a composite material by an electric pulse, the composite material being obtained by bonding or joining a plurality of conductors to each other with an insulating member, the electric pulse decomposition method including a protrusion formation step for forming a protrusion in a specific site, on a side on which the composite material is arranged, of at least one of the plurality of conductors, and a separation step for separating the plurality of conductors in the composite material 1 by respectively bringing electrodes into contact with surfaces of the plurality of conductors and applying an electric pulse between the electrodes to destroy the insulating member. This makes it possible to separate the plurality of conductors from the composite material by making a shock wave caused by a current of the dielectric breakdown functioning as an adhesive to effectively destroy the insulating member.

Abstract: An exemplary substance is provided that permeates the blood-brain barrier and shows a property of penetrating into the brain. Further, exemplary use of the substance as a drug carrier is provided for delivering into the brain, and a pharmaceutical composition containing the substance. Additionally, exemplary lactose-modified cyclodextrin or dendrimer/glucuronyl glucosyl-cyclodextrin is provided that permeates the blood-brain barrier and shows a property of penetrating into the brain. Exemplary blood-brain barrier permeable pharmaceutical composition is also provided which comprises a lactose-modified cyclodextrin or dendrimer/glucuronyl glucosyl-cyclodextrin, and a drug.

Abstract: In the conventional eFPGAs, there have been two challenges: the first one being size reduction of the logic cells to improve the implemented logic density, and the second one being minimization of the speed difference with the ASIC. According to the present embodiment, there is provided a method for configuring a programmable logic circuit represented by a gate-level netlist, wherein this is done by assigning the gate-level netlist to a 4-input, 3-output combinational logic cell, which is composed of a combination of 3 of 2-input (m-input) basic logic cells, wherein the combinational logic cell covers 3(n) nodes constituting a graph of the netlist.

Abstract: A pathological mechanism in FOP patients is further revealed, and development of a novel therapeutic drug, therapeutic method, diagnostic method, etc. utilizing an obtained finding is provided. The inventors have found a novel finding that in FOP, ectopic ossification, which occurs by an inflammation due to an injury, etc., is mediated by PAR1 to occur. From this finding, the inventors completed the present invention relating to a drug, etc. characterized by suppressing ectopic ossification in FOP by inhibiting PAR1.

Abstract: Provided is a method which is for analyzing ionic components in pure water and in which sample ultrapure water is concentrated and analyzed by an analysis means, the method being characterized in that the sample ultrapure water is concentrated by means of an electrodialyzer. The electrodialyzer is a second electrodialyzer (20) in which sample ultrapure water is passed through a first generation chamber (27), high-purity nitric acid aqueous solution is passed through a second generation chamber (28), and concentrated water for analysis is extracted from the second generation chamber (28). The high-purity nitric acid aqueous solution passing through the second generation chamber (28) is generated by dialyzing a potassium nitrate aqueous solution by a first electrodialyzer (10).

Abstract: An object of the present invention is to provide a novel preventive or therapeutic agent for muscular atrophy. The present invention provides a preventive or therapeutic agent for muscular atrophy containing a Dll4 function inhibitor as an active ingredient. The Dll4 function inhibitor is selected from the group consisting of a binding inhibitor between Dll4 and Notch2, a Dll4 expression inhibitor, or an inhibitor of binding of collagen to LL4.

Abstract: A dispersion of exfoliated particles which includes at least one nitrogen-containing basic compound (A) which is a tertiary amine or a quaternary ammonium hydroxide having at least one alkyl group having 3 or 4 carbon atoms, and in which exfoliated particles (C) produced by interlayer-exfoliating a proton-type layered polysilicate compound (B) are dispersed in an aqueous solution (D) having 10 vol % to 90 vol % of an alcohol having 1 to 3 carbon atoms; and a film-forming composition, a porous body-forming composition, an LB film, a coating film, a free-standing membrane, a proton conductor, an electrolyte membrane for fuel cells, and a porous body each containing exfoliated particles.

Abstract: An influenza vaccine composition to be intranasally administered, including an influenza antigen to which TGDK is linked via a chemical bond.

Abstract: An object of the present invention is to provide a method for determining that a subject is at risk of suffering or is suffering from COVID-19. The present invention provides a method for determining whether a subject that is a mammal is at risk of suffering or suffering from COVID-19, the method including a step of detecting the amount of at least one modified nucleoside selected from the group consisting of 6-threonylcarbamoyl adenosine (t6A) and 2-thiomethyl,6-threonylcarbamoyl adenosine (ms2t6A) in a sample derived from the subject.

Abstract: A dispersion of exfoliated particles which includes at least one nitrogen-containing basic compound (A) which is a tertiary amine or a quaternary ammonium hydroxide having at least one alkyl group having 3 or 4 carbon atoms, and in which exfoliated particles (C) produced by interlayer-exfoliating a proton-type layered polysilicate compound (B) are dispersed in an aqueous solution (D) having 10 vol % to 90 vol % of an alcohol having 1 to 3 carbon atoms; and a film-forming composition, a porous body-forming composition, an LB film, a coating film, a free-standing membrane, a proton conductor, an electrolyte membrane for fuel cells, and a porous body each containing exfoliated particles.

Abstract: An inactivated whole-virus influenza vaccine may have its antibody-inducing ability is maintained or enhanced and may cause fewer side reactions. A method for preparing an inactivated whole-virus influenza vaccine may use an embryonated chicken egg method, including subjecting a virus solution including a whole influenza virus collected from embryonated chicken eggs to a hypotonic treatment.

Abstract: An object of the present invention is to reveal a role of a stem cell control factor including Matrin-3 in cancer exhibiting neural differentiation including small cell lung cancer, and develop a medicine useful for treating cancer and the like based on the role. Among cancers having the cancer stem cell controlling mechanism, in cancer exhibiting the differentiation potency, the peculiar balance where both of expression of a stem cell maintenance factor and expression of a differentiation promoting factor are higher as compared with normal cells is retained. Additionally, in undifferentiated cancer, the peculiar balance where expression of a stem cell maintenance factor is higher as compared with normal cells is retained. In cancer in which the cancer stem cell controlling mechanism exists, these peculiar balances of a stem cell control factor different from the balance of normal cells exist.

Abstract: It is an object of the present invention to provide antibodies against coronavirus (SARS-CoV-2). It is also an object of the present invention to provide a pharmaceutical composition against coronavirus infection using the antibody. According to the present invention, an antibody or antigen-binding fragment thereof that binds to the receptor-binding domain present in the spike protein of coronavirus and is capable of neutralizing the coronavirus, and a pharmaceutical composition for the prevention or treatment of coronavirus infection containing the antibody or antigen-binding fragment, are provided.

Abstract: [Object] To clarify the mechanism associated with neuropathy in methylmalonic acidemia and to develop a new therapeutic drug or the like for neuropathy in organic acidemia on the basis of this finding. [Solving Means] The inventors established technologies for the establishment of iPS cells derived from a methylmalonic acidemia patient and establishment of a stable maintenance and culturing method using peripheral blood lymphocytes of a methylmalonic acidemia patient, and for the differentiation of methylmalonic acidemia patient-derived iPS cells into nerve cells. The inventors made clear that neuropathy in organic acidemia can be treated and prevented by replenishing cAMP using a series of these experiment technologies. The drug of the invention treats or prevents neuropathy by increasing cAMP in organic acidemia.

Abstract: The present invention provides a method for highly sensitively and highly specifically detecting a kidney cancer. According to the present invention, there is provided, for example, a method for detecting a kidney cancer in a subject, comprising diluting a urine sample obtained from the subject at a predetermined ratio, and determining whether or not nematodes exhibit attraction behavior toward the diluted urine sample, wherein the predetermined ratio is 200 or more.

Abstract: Provided are a transthyretin tetramer stabilizing agent and a preventing agent or progression suppressing agent for transthyretin amyloidosis. The present invention relates to a transthyretin tetramer stabilizing agent including a hydrophobic licorice extract containing a licorice glabra polyphenol, and to a preventing agent or progression suppressing agent for transthyretin amyloidosis including a hydrophobic licorice extract containing a licorice glabra polyphenol.

Abstract: Provided are a transthyretin tetramer stabilizing agent and a preventing agent or progression suppressing agent for transthyretin amyloidosis. The present invention relates to a transthyretin tetramer stabilizing agent including glabridin, glabrene, and glabrol, and to a preventing agent or progression suppressing agent for transthyretin amyloidosis including glabridin, glabrene, and glabrol.

Abstract: A mucosal adjuvant may have high mucosal immunogenicity and high safety and be useful in the preparation of mucosal vaccines, and a mucosal vaccine composition may include the same. Such mucosal adjuvant may include TGDK. A method for preparing the mucosal vaccine composition may include mixing TGDK with an immunogen.

Abstract: An exemplary composition can be provided which includes an identified substance that induced cell reprogramming. Cells can also be provided having pluripotency having high safety when applied to regenerative medicine, using the composition, and a production method therefor. A cell reprogramming-inducing composition can include at least one 30S ribosome protein selected from the group consisting of 30S ribosome protein S2, 30S ribosome protein S8 and 30S ribosome protein S15 as a substance that reprograms cells derived from a mammalian animal is provided. Further, an exemplary production method for cells having pluripotency from somatic cells using the composition can be provided.

Abstract: An RNA methyltransferase inhibitor comprising sulfonamide-based compounds and/or pyrazoline-based compounds is provided